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ABSTRACT 
Objective: Promethazine theoclate is a BCS Class II drug having anti-histaminic property and mainly used for the treatment of motion sickness and 
postoperative emesis. The main objective of the research work was to formulate and optimize immediate release pellets of promethazine theoclate 
by using the extrusion-spheronization technique to offer immediate release dosage form suitable for treatment of nausea and vomiting associated 
with motion sickness and post-operative conditions. 
Methods: Immediate release pellets of promethazine theoclate were prepared by using microcrystalline cellulose (MCC) and corn starch as filler 
and disintegrant respectively along with other excipients. Pellet formulation was further optimized for bulk density, disintegration time and percent 
drug release after 10 min. using 32 
Results: Optimised pellet formulation contains 2.5:4.5:1 ratio of MCC: Corn Starch: Drug and spheronization time of 60 seconds showing highest 
percent yield of 78% and immediate drug release of 100.52±0.65% after 10 min.  
factorial design. Formulations were also characterized for drug-polymer interactions using Differential Scanning 
Calorimetry (DSC), surface morphology by Scanning Electron Microscopy (SEM) and other physicochemical properties.  
Conclusion: Promethazine theoclate pellets formulated in this study can serve as an alternative to tablet dosage form which can give immediate 
drug release for treatment of motion sickness and postoperative emesis. 
Keywords: Promethazine theoclate, Immediate release pellets, Multiparticulate drug delivery, Extrusion-spheronisation, Factorial design 




Promethazine theoclate is BCS Class II, H1
Pellets formulation as multiple-unit dosage forms are preferred over 
single-unit dosage forms due to stable plasma profiles, free dispersion in 
GI tract maximizing GI absorption and minimizing local mucosal side 
effects. Among the various types of multiple-unit dosage forms, pellets 
have attracted more attention due to their unique clinical and technical 
advantages. Pellet drug delivery system offers various therapeutic 
advantages such as dose tailoring as well as it helps in reducing inter and 
intrapatient variability by reducing fluctuations in peak plasma 
concentrations with no significant reduction in bioavailability [7, 8].  
 antihistaminic drug 
mainly used in the treatment of motion sickness and postoperative 
emesis [1, 2]. It has 25% bioavailability due to its poor aqueous 
solubility which is the major limiting factor for its absorption and 
delayed onset of action [3]. Promethazine theoclate tablets are 
available in the market as immediate release single-unit dosage form 
for oral administration. Formulation development of transdermal 
patch, SLN, suppository and gel for promethazine theoclate are also 
explored in research for different routes of administration [4-6]. 
Microcrystalline cellulose (MCC) and Corn starch are most common 
excipients utilized for the production of pellets via extrusion 
spheronisation technique. It has ideal rheological properties well 
suited for the process [9, 10]. In case of a drug having low solubility, 
MCC alone can give prolonged drug release profil e [11] due to the 
lack of disintegration of MCC-based pellets. It may also show drug 
adsorption onto the surface of MCC fibr e [12, 13] which can be 
minimized by using Corn starch in combination with MCC [14] to get 
an immediate release of the drug. 
The objective of this study was to formulate promethazine theoclate 
immediate release pellets using MCC and Corn starch and optimize 
the formula using 32
MATERIALS AND METHODS 
 factorial design. 
Materials 
Promethazine theoclate was obtained as a gift sample from Mehta 
Pharmaceutical Pvt. Ltd., Mumbai. Microcrystalline cellulose (Avicel 
PH101) was purchased from Research Lab, Mumbai. Corn starch, 
sodium starch glycolate, lactose (monohydrate), isopropyl alcohol and 
HCl were purchased from Loba Chemie, Mumbai. Polyvinylpyrrolidone 
(PVP) K-30 was purchased from Himedia Laboratories Pvt. Ltd., Mumbai.  
Methods 
Construction of calibration curve of promethazine theoclate in 
0.1 N HCl 
Accurately weighed 10 mg of the promethazine theoclate was dissolved 
in 10 ml methanol and diluted to 100 ml with 0.1N HCl. The prepared 
stock solution was subsequently diluted to get the concentrations of 5, 
10, 15, 20, 25, 30, 35, 40, 45, 50 and 55 μg/ml of promethazine theoclate 
respectively. The absorbance of these solutions was measured at 278 nm 
using UV/Visible spectrophotometer (Shimadzu). Calibration curve was 
plotted as shown in fig. 1. 
 
 
Fig. 1: Calibration curve of promethazine theoclate in 0.1N HCl 
 
Drug-excipient compatibility study  
Investigation of the potential interaction of promethazine theoclate 
and other excipients was done by recording and analysing 
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thermograms using DSC (DSC 60 Shimadzu, Japan) for pure drug and 
physical mixture of the drug with excipients. Samples were heated at 
a heating rate of 10 °C/min. in the range of 25–400 °C using standard 
aluminium sample pans. DSC thermograms were observed for 
potential interactions. 
Preparation of pellet formulation by extrusion-spheronization 
technique  
Preliminary screening of excipients 
Preliminary screening for selection of binder, other excipients and 
instrument parameters was done by visual inspection and flow 
properties of the pellets obtained from the initial studies. It was 
observed that PVP K30, as a binder, gave acceptable spherical pellets 
with good yield, low friability and satisfactory flow properties. Based on 
the observations, 7% of PVP K30, 8% of SSG and speed of 800rpm with 5 
mm friction plate were selected as formulation and process parameters. 
Preparation of drug-loaded pellets 
Pellets were prepared by following steps using lab scale spheronizer 
(Shakti Pharmatech). 
Preparation of wet mass 
The powder mixture was prepared by homogenous blending of 
microcrystalline cellulose, corn starch, PVP K-30 and sodium starch 
glycolate. Binder solution containing PVP K30 in a mixture of purified 
water and isopropyl alcohol was added separately to dry mixture with 
kneading. Successive pauses were taken for the addition of the liquid 
components for proper kneading to obtain a damp mass of appropriate 
consistency for the extrusion process [10, 11]. 
Extrusion 
Prepared wet mass was immediately extruded through sieve 
number 14 (B. S. S.) to get compact cylindrical extrudates of uniform 
diameter.  
Spheronization 
The extrudates were spheronised using lab Spheronizer (Shakti 
Pharmatech) at 800 rpm with 5 mm friction plate to get spherical 
pellets. Wet pellets were dried in Fluid Bed Dryer (FBD) for 10 min 
keeping product temperature below 65 °C. 
Formula optimization 
Preliminary studies showed a significant effect of concentration of 
MCC and Corn starch on bulk density, disintegration time and 
percent drug release of pellets. These two parameters were selected 
as Independent variables for the formulation optimization of 
promethazine theoclate loaded pellets using 32
 
 factorial design. Nine 
batches were prepared at levels of-1, 0,+1 of independent variables 
as shown in table 1. 
Table 1: Composition of promethazine theoclate pellets for factorial design 
Batch code MCC (g) Corn starch (g) Lactose (g) SSG (g) PVP K-30 (g) Drug (g) 
I 3 7 4.25 2 1.75 2 
II 3 8 3.25 2 1.75 2 
III 3 9 2.25 2 1.75 2 
IV 4 7 3.25 2 1.75 2 
V 4 8 2.25 2 1.75 2 
VI 4 9 1.25 2 1.75 2 
VII 5 7 2.25 2 1.75 2 
VIII 5 8 1.25 2 1.75 2 
IX 5 9 0.25 2 1.75 2 
All batches were evaluated for response variables, bulk density, disintegration time and percent drug release. The data obtained was analyzed using 
Design Expert 7.0.0 software to generate polynomial equation, contour plots and design space.  
 
Characterization of drug loaded pellets 
Developed formulations of pellets were characterized for the 
following properties. 
Particle size 
Photomicrograph of pellets was taken and analysed using Image J 
software to determine its particle size.  
Morphology 
The surface morphology of pellets was examined using the scanning 
electron microscope (FEI Nova NanoSEM 450) which was operated at 
3.0 kV and 5.0kV at magnifications of 103X, 250X, 1000X and 5000X. 
Bulk density  
Apparent bulk density is determined by pouring a weighed quantity 
of pellets into a graduated cylinder and measuring the volume and 
weight. Bulk density is calculated using the following formula:  
Bulk density =
Weight of pellets
Bulk volume of pellets
 
Hardness 
The hardness of pellets was measured by using a digital pellet 
hardness tester (Veego).  
Friability [16] 
Friability of pellets was checked by using Friability test apparatus 
(Roche Friabilator) at 25 rpm for 4 min. Percent friability was 







W1= Initial weight of pellets 
W2= Final weight of pellets after removing fines. 
Disintegration time 
The disintegration time of pellets was checked by putting 250 mg of 
pellets in 50 ml distilled water with continuous shaking in water 
bath shaker at 37 °C till complete disintegration. 
Drug content 
About 250 mg of the pellets were taken and crushed in a mortar 
to obtain a fine powder. 25 mg powder was taken and dissolved 
in 10 ml methanol and diluted up to 50 ml with 0.1N HCl, 
sonicated for 5 min and volume was made up to 100 ml with 
0.1N HCl. The absorbance of the resulting solution was measured 
at 278 nm using the UV/Visible spectrophotometer.  
The concentration of drug in solution was calculated using 
calibration curve. 
Drug content (%) was calculated using following formula:  
Drug content (%)  =
Actual amount of Promethazine theoclate found in pellets
Theoretical amount of Promethazine theoclate in pellets × 100 
Rupali et al. 
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In vitro dissolution studies 
In vitro dissolution studies were performed using USP type 1 
apparatus (basket). An accurately weighed sample of pellets 
containing an equivalent amount of 25 mg of promethazine 
theoclate was filled into gelatine capsules and dissolution studies 
were carried out into 900 ml of 0.1N HCl, maintained at a 
temperature of 37 °C±0.5 °C at 100 rpm. At different time intervals, 
10 ml aliquot of the sample was withdrawn and the volume was 
replaced with an equivalent amount of dissolution medium kept at 
37 °C. The collected samples were filtered and the absorbance was 
measured at 278 nm. Percent drug release was compared with drug 
release from marketed formulation (Avomine tablet; Promethazine 
theoclate 25 mg; Mfg. by: sanofi aventis). 
Stability studies of optimized batch 
Stability studies of the optimized formulations were performed 
using gelatin capsules filled with developed promethazine theoclate 
pellets at accelerated conditions of 40 °C temperature and 75 % RH 
for 30 d as per the International Conference on Harmonization (ICH) 
guidelines 
Samples were withdrawn after 30 d and subjected to analysis for 
specified parameters.  
RESULTS AND DISCUSSION 
Drug-excipient compatibility studies for promethazine theoclate 
along with the excipients used in the formulation was checked using 
DSC technique. As shown in fig. 2, DSC thermogram of pure 
promethazine theoclate and physical mixture of the drug with 
excipients showed sharp endothermic peaks at 180.1 °C and 178.9 
°C respectively, indicating no significant difference in peak position 
and compatibility of the drug with excipients. 
The flow properties of pellets were evaluated by checking the angle 
of repose. An angle of repose (θ)<30 ° indicates free-flowing 
material and >40° indicates poor flow. Values for the angle of repose 
(θ), for all factorial batches of pellets, were found to be in the range 
of 20.55 °±0.02 to 28.35 °±0.02 indicating free-flowing pellets which 
can be easily filled into capsules.  
Percent friability of prepared pellets was found to be within 
0.32±0.35 to 0.80±0.19 which was acceptable as the standard limit 
for percent friability which is <1%. It indicates sufficient mechanical 
integrity, strength and hardness. The particle size of all factorial 
batches was found within 0.87±0.42 to 1.41±0.18 mm. Data of 




Fig. 2: Overlay of DSC thermogram of promethazine theoclate and physical mixture with excipients 
 
Table 2: Evaluation of promethazine theoclate loaded pellets 
Batch 
code 








% Drug release after 10 
min(Y) 2)
Bulk density 
(g/ml)# * (Y3) 
I 28.35±0.02 0.57±0.24 1.41±0.18 33.89 101.71±0.34 0.71±0.02 
II 24.87±0.03 0.42±0.02 1.31±0.23 24.30 93.67±0.27 0.68±0.03 
III 23.96±0.02 0.72±0.40 1.32±0.22 23.20 93.82±0.45 0.71±0.02 
IV 20.55±0.02 0.62±0.16 1.34±0.24 56.25 85.94±0.40 0.72±0.02 
V 25.42±0.01 0.37±0.09 1.29±0.22 40.21 82.05±0.45 0.63±0.01 
VI 28.07±0.01 0.32±0.35 1.11±0.24 28.88 85.14±0.59 0.66±0.01 
VII 23.80±0.01 0.43±0.42 0.87±0.42 59.00 77.43±0.79 0.65±0.01 
VIII 23.90±0.01 0.80±0.19 1.01±0.19 53.08 87.75±0.65 0.59±0.01 
IX 24.56±0.02 0.58±0.35 1.29±0.37 21.05 100.52±0.65 0.58±0.02 
Values are expressed as mean±SD, *n = 3, # n = 3, ** n=2, $
 
n=200 
Disintegration time and percent drug release after 10 min. are the 
important parameters to be optimized as far as drug release from 
immediate release pellets is concerned. Bulk density plays a critical 
role when pellets need to be filled in capsules in order to get correct 
dose to be delivered.  
Disintegration time, percent drug release and bulk density were 
found to vary with changing concentration of MCC and Corn starch.  
To estimate the effect of concentration MCC and Corn starch on 
disintegration time, percent drug release and bulk density, 32
Polynomial equations generated by design expert software are explained 
herewith for its interpretation of effect on response parameters. 
 
factorial design was investigated. Statistical analysis of data by 
ANOVA suggested linear model significant for disintegration time 
with p-value 0.0102 and quadratic model significant for percent 
drug release after 10 min. and bulk density with p values 0.0353 and 
0.0167 respectively. 
Disintegration time (Y1) = 37.76+8.62*X1-12.67*X2 
Positive coefficient of X
………. (1) 
1 in equation (1) indicated increase in the 
disintegration time (Y1) with increase concentration of MCC up to 
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certain concentration, and negative coefficient of X2 indicates 
decrease in its response (Y1
  
) with increase in concentration of Corn 
starch up to certain concentration since Corn starch acts as 
disintegrating agent, and thereby reduces disintegration time of 
pellets. The response plot and counterplots in fig. 3A and 3B 
respectively are indicative of the relative effect of concentration of 
MCC and Corn starch on disintegration time of promethazine 
theoclate loaded pellets. 
 
Fig. 3: Different plots showing effect of independent variables on Disintegration time of pellets, (A) Counterplot showing the relationship 
between various levels of two independent variables, (B) Response surface plot showing the influence of the concentration of MCC and 
Corn Starch on the Disintegration time 
 
Percent drug release after 10 min (Y2) = 82.42-
3.92*X1+2.40*X2+7.75*X1*X2+8.11*X1 2+2.94*X2 2
From equation (2), it is observed that negative coefficient of X
… (2) 
1 
indicates a decrease in percent drug release after 10 min (Y2) with 
an increase in the concentration of MCC whereas the positive 
coefficient of X2
  
 indicates an increase in percent drug release after 
10 min with an increase in the concentration of Corn starch till 
certain concentration level. Increase in Corn starch might be 
increasing disintegration of pellets leading to faster drug release. 
The 3D response plot and counterplots indicating the relative effect 
of concentration of MCC and Corn starch on percent drug release 
after 10 min of promethazine theoclate loaded pellets are shown in 
fig. 4A and 4B respectively. 
 
Fig. 4: Different plots showing the effect of independent variables on % drug release of pellets after 10 min, (A) Counterplot showing the 
relationship between various levels of two independent variables, (B) Response surface plot showing the influence of the concentration 
of MCC and Corn Starch on the % drug release of pellets after 10 min 
 
Bulk density (Y3)= 0.64-0.047*X1-0.020*X2-0.018*X1*X2-
0.018*X1 2+0.037*X2 2
Equation (3), indicated a decrease in the bulk density (Y
…. (3) 
3
The response plot and counterplots are shown in fig. 6A and 6B 
respectively which are indicative of a relative effect of 
concentration of MCC and Corn starch on the bulk density of 
promethazine theoclate loaded pellets. 
) with 
an increase in the concentration of MCC and decrease in bulk 
density with increase in the concentration of Corn starch up to 
certain concentration level, might be due to a reduction in the 
total content of excipients.  
Rupali et al. 




Fig. 6: Different plots showing the effect of independent variables on the bulk density of pellets, (A) Counterplot showing the relationship 
between various levels of two independent variables, (B) Response surface plot showing the influence of the concentration of MCC and 
corn Starch on the bulk density of pellets 
 
Though excipients are considered as inactive ingredients, they have 
a significant impact on functional properties of the formulation. It is 
known that MCC when extruded to get the dense material, it tends to 
disintegrate very slowly with the absence of disintegrating agent as 
well as an increase in the concentration of MCC increases 
compatibility of powder mixture leading to lower disintegration 
time [17].  
Considering these facts, here increase in the concentration of MCC 
decreases disintegration time, a decrease in bulk density of pellets. 
Due to reduced disintegration time, it further leads to decrease in 
percent drug release. On the contrary, Corn starch being a 
disintegrant, cause disintegration of pellets by swelling action [18] 
and thereby enhancing the drug release from pellets. 
With reference to the graphical and mathematical analysis of data by 
experimental design formulation composition of batch IX of 
promethazine, theoclate was found to give desired results at higher 
concentrations of MCC, 5% and Corn starch 9%.  
Optimized formulation was further characterized by SEM analysis to 
evaluate the morphology of pellets such as pellet shape and surface 
characteristics.  
It was found to have a spherical shape and smooth surface with 
minimal pores, indicating uniformity in pellets as shown in fig. 7. 
The observed values of optimized batch during the response 
variables are compared with the predicted values. From the results 
observed (table 3), it was found that mathematical models 
generated were statistically significant and valid for predicting 




Fig. 7: SEM images of optimized formulation batch IX; A) at 
103X, B) at 250X, C) at 1000X, and D) at 5000 X 
 
Table 3: Validation of optimised formulation (Batch code: IX) 
Parameters Predicted value Actual (experimental) value 
Bulk density (g/ml) 0.58 0.59 
Angle of repose( °) 24.65 24.56 
Yield (%) 71.88 78.00 
Particle size (mm) 1.285 1.21 
Hardness (kg/cm2 0.07 ) 0.08 
Friability (%) 0.55 0.58 
Drug release after 10 min. (%)  99.69 100.52 
 
An optimized batch of promethazine theoclate pellets (IX) was filled 
into capsule shell equivalent to a required dose of the drug and it’s 
percent release was compared with the marketed formulation of 
promethazine theoclate tablet (Avomine tablet). Both formulations 
showed the comparative release of > 85% within 30 min. which 
indicates immediate drug release.  
The comparative release profile is shown in fig. 8. 
Stability studies of optimized formulation indicated no significant 
change in the appearance of pellets, its assay, and disintegration 
time and percentage drug release after 30 d of storage at accelerated 
conditions.
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Fig. 8: Comparative percent release profile of optimized formulation of pellets filled in a capsule with the marketed product (Avomine 
tablet; sanofi aventis) 
 
CONCLUSION 
In the present study, systematic efforts were made to develop and 
optimize promethazine theoclate loaded immediate release pellets 
as multiparticulate drug delivery system which can be delivered 
after filling into a gelatin capsule. 
Optimization of the formulation was demonstrated by using 32
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factorial design and investigation using polynomial equations, 
surface response plots and counterplots generated during the 
investigation. Optimised formulation (IX) was found to show highest 
percent yield of 91.4, the bulk density of 0.58±0.02 g/ml with good 
flow properties having a 24.56±0.02 °angle of repose, 0.58±0.35 % 
friability, and disintegration time of 21.05 seconds. The particle size 
of optimized formulation was found to be 1.29±0.37 mm with 
100.52±0.65 % drug release after 10 min. Promethazine theoclate 
loaded pellets showed the significant effect of independent variables 
i.e. concentration of MCC and Corn starch on dependent variables i.e. 
bulk density, disintegration time and percent drug release after 10 
min which are critical parameters in terms of dosage, disintegration 
and drug release respectively when pellets are to be delivered into 
the capsule. Percent drug release of optimized formulation (IX) was 
found to be comparable with marketed formulation (Avomine 
Tablet). Optimized formulation (IX) was found to be stable at 40 °C 
and 75%RH after 30 d of storage. 
Promethazine theoclate pellets formulated in this study can be used as 
an alternative to tablet dosage form which can give immediate drug 
release for treatment of motion sickness and post-operative emesis.  
We are thankful to Mehta Pharmaceutical, Mumbai for providing the 
gift sample of promethazine theoclate. 
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